Ketum and Pain Tolerence

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03414099

Enrollment

Registered

2018-01-29

Start date

2018-01-23

Completion date

2021-12-30

Last updated

2021-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain

Keywords

Pain, Kratom, Ketum, mitragynine

Brief summary

The study aim is to evaluate potential analgesic properties of ketum using the cold pressor task.

Detailed description

Participants in the proposed study will be individuals who report consuming ketum more than once a day, daily for the past 12 months. The study is a placebo-controlled, double-blind within-subject repeated mesaures design. Participants will ingest a sequence of ketum and placebo drinks prepared by pharmacologists at USM Centre for Drug Research and their pain tolerance will be measured by the cold pressor task after ingesting ketum or placebo.

Interventions

DRUGKetum

Ketum (Mitragyna speciosa) is an indigenous plant of Southeast Asia reported to have medicinal value in traditional culture

DRUGPlacebo

Placebo drink matched for taste and appereance

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

OTHER

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Masking description

Ketum and placebo drinks will be matched for taste and appearence. Each study participant will receive a sequence of ketum and placebo drinks in random order.

Intervention model description

Within-subject, repeated measures

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

Individuals who report drinking ketum decoction more than once a day, daily for the past 12 months. \-

Exclusion criteria

(1) tested positive for illicit drug use including morphine, cannabis, methamphetamine, amphetamine, methadone, benzodiazepine and ketamine; (2) have current or previous history of psychological or neurological problems (self-report); (3) have current or previous alcohol use history (self-report); (4) HIV infections; (5) history of chronic liver disease (e.g. cirrhosis, hepatitis A, B, C, etc.) 6) non-alcoholic fatty liver disease; (7) history of coronary heart disease and diabetes; (8) existing chronic pain condition and (9) history of psychiatric disorders.

Design outcomes

Primary

Measure	Time frame	Description
Pain tolerance	3 hours	The duration (seconds) participants can keep their hands immersed in the water bath

Countries

Malaysia

Contacts

Primary ContactMohd Bazlan Hafidz Mukrim, BSc

bazlan@usm.my609-7672354

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026